173 related articles for article (PubMed ID: 37010741)
21. Taking the EZ way: Targeting enhancer of zeste homolog 2 in B-cell lymphomas.
Morschhauser F; Salles G; Batlevi CL; Tilly H; Chaidos A; Phillips T; Burke J; Melnick A
Blood Rev; 2022 Nov; 56():100988. PubMed ID: 35851487
[TBL] [Abstract][Full Text] [Related]
22. Trace Elements, PPARs, and Metabolic Syndrome.
Shi Y; Zou Y; Shen Z; Xiong Y; Zhang W; Liu C; Chen S
Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32283758
[TBL] [Abstract][Full Text] [Related]
23. Network pharmacology and molecular docking approaches to elucidate the potential compounds and targets of Saeng-Ji-Hwang-Ko for treatment of type 2 diabetes mellitus.
Ko M; Kim Y; Kim HH; Jeong S; Ahn D; Chung SJ; Kim H
Comput Biol Med; 2022 Oct; 149():106041. PubMed ID: 36049411
[TBL] [Abstract][Full Text] [Related]
24. [The role of PPARs and their isoforms in metabolic disorders related to insulin resistance and diabetes].
Kravchenko NA; Iarmysh NV
Tsitol Genet; 2011; 45(3):68-78. PubMed ID: 21774406
[TBL] [Abstract][Full Text] [Related]
25. Natural PPARs agonists for the treatment of nonalcoholic fatty liver disease.
Pan J; Zhou W; Xu R; Xing L; Ji G; Dang Y
Biomed Pharmacother; 2022 Jul; 151():113127. PubMed ID: 35598367
[TBL] [Abstract][Full Text] [Related]
26. The Role of PPARs in Disease.
Wagner N; Wagner KD
Cells; 2020 Oct; 9(11):. PubMed ID: 33126411
[TBL] [Abstract][Full Text] [Related]
27. Peptide Helix-Y
Carrillo-Tripp M; Reyes Y; Delgado-Coello B; Mas-Oliva J; Gutiérrez-Vidal R
PPAR Res; 2023; 2023():8047378. PubMed ID: 37096195
[TBL] [Abstract][Full Text] [Related]
28. Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase enhancer of zeste homologue 2.
Ougolkov AV; Bilim VN; Billadeau DD
Clin Cancer Res; 2008 Nov; 14(21):6790-6. PubMed ID: 18980972
[TBL] [Abstract][Full Text] [Related]
29. ANLN-induced EZH2 upregulation promotes pancreatic cancer progression by mediating miR-218-5p/LASP1 signaling axis.
Wang A; Dai H; Gong Y; Zhang C; Shu J; Luo Y; Jiang Y; Liu W; Bie P
J Exp Clin Cancer Res; 2019 Aug; 38(1):347. PubMed ID: 31395079
[TBL] [Abstract][Full Text] [Related]
30. Role of the EZH2 histone methyltransferase as a therapeutic target in cancer.
Italiano A
Pharmacol Ther; 2016 Sep; 165():26-31. PubMed ID: 27179746
[TBL] [Abstract][Full Text] [Related]
31. Naturally occurring anti-cancer agents targeting EZH2.
Shahabipour F; Caraglia M; Majeed M; Derosa G; Maffioli P; Sahebkar A
Cancer Lett; 2017 Aug; 400():325-335. PubMed ID: 28323035
[TBL] [Abstract][Full Text] [Related]
32. EZH2-Targeted Therapies in Cancer: Hype or a Reality.
Eich ML; Athar M; Ferguson JE; Varambally S
Cancer Res; 2020 Dec; 80(24):5449-5458. PubMed ID: 32978169
[TBL] [Abstract][Full Text] [Related]
33. Identification of Four New Chemical Series of Small Drug-Like Natural Products as Potential Neuropilin-1 Inhibitors by Structure-Based Virtual Screening: Pharmacophore-Based Molecular Docking and Dynamics Simulation.
Sabki A; Khelifi L; Kameli A; Baali S
Chem Biodivers; 2023 Mar; 20(3):e202200933. PubMed ID: 36799050
[TBL] [Abstract][Full Text] [Related]
34. [Research progress on active ingredients of traditional Chinese medicines improved insulin resistance based on PPARs targets].
Jiang HJ; Zhang XJ; Zhang H; Yan JZ
Zhongguo Zhong Yao Za Zhi; 2015 Nov; 40(22):4355-8. PubMed ID: 27097406
[TBL] [Abstract][Full Text] [Related]
35. Genome-wide expression analysis reveals six contravened targets of EZH2 associated with breast cancer patient survival.
Kumari K; Das B; Adhya AK; Rath AK; Mishra SK
Sci Rep; 2019 Feb; 9(1):1974. PubMed ID: 30760814
[TBL] [Abstract][Full Text] [Related]
36. Both EZH2 and JMJD6 regulate cell cycle genes in breast cancer.
Biswas A; Mukherjee G; Kondaiah P; Desai KV
BMC Cancer; 2020 Nov; 20(1):1159. PubMed ID: 33246425
[TBL] [Abstract][Full Text] [Related]
37. Long noncoding RNA UPK1A-AS1 indicates poor prognosis of hepatocellular carcinoma and promotes cell proliferation through interaction with EZH2.
Zhang DY; Sun QC; Zou XJ; Song Y; Li WW; Guo ZQ; Liu SS; Liu L; Wu DH
J Exp Clin Cancer Res; 2020 Oct; 39(1):229. PubMed ID: 33121524
[TBL] [Abstract][Full Text] [Related]
38. MiR-26a and miR-138 block the G1/S transition by targeting the cell cycle regulating network in prostate cancer cells.
Erdmann K; Kaulke K; Rieger C; Salomo K; Wirth MP; Fuessel S
J Cancer Res Clin Oncol; 2016 Nov; 142(11):2249-61. PubMed ID: 27562865
[TBL] [Abstract][Full Text] [Related]
39. [Peroxisome proliferator-activated receptors (PPARs) in obesity and insulin resistance development].
Alemán G; Torres N; Tovar AR
Rev Invest Clin; 2004; 56(3):351-67. PubMed ID: 15612519
[TBL] [Abstract][Full Text] [Related]
40. MicroRNA-638 induces apoptosis and autophagy in human liver cancer cells by targeting enhancer of zeste homolog 2 (EZH2).
Zhang H; Liang H; Wu S; Zhang Y; Yu Z
Environ Toxicol Pharmacol; 2021 Feb; 82():103559. PubMed ID: 33290872
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
